328 related articles for article (PubMed ID: 14667200)
41. Activity of thymidine kinase and of polymerase alpha as well as activity and gene expression of deoxycytidine deaminase in leukemic blasts are correlated with clinical response in the setting of granulocyte-macrophage colony-stimulating factor-based priming before and during TAD-9 induction therapy in acute myeloid leukemia.
Jahns-Streubel G; Reuter C; Auf der Landwehr U; Unterhalt M; Schleyer E; Wörmann B; Büchner T; Hiddemann W
Blood; 1997 Sep; 90(5):1968-76. PubMed ID: 9292531
[TBL] [Abstract][Full Text] [Related]
42. Proportion of blasts with a clear halo around nucleoli at the end of induction therapy of acute myeloid leukemia correlates with achievement of complete remission, remission duration and relapse.
Emura I; Chou T; Ishiguro T; Kakihara T; Naito M; Yoshizawa H; Arakawa M
Pathol Int; 1998 Jul; 48(7):526-35. PubMed ID: 9701015
[TBL] [Abstract][Full Text] [Related]
43. Postremission therapy with low-dose interleukin 2 with or without intermediate pulse dose interleukin 2 therapy is well tolerated in elderly patients with acute myeloid leukemia: Cancer and Leukemia Group B study 9420.
Farag SS; George SL; Lee EJ; Baer M; Dodge RK; Becknell B; Fehniger TA; Silverman LR; Crawford J; Bloomfield CD; Larson RA; Schiffer CA; Caligiuri MA
Clin Cancer Res; 2002 Sep; 8(9):2812-9. PubMed ID: 12231521
[TBL] [Abstract][Full Text] [Related]
44. Immunophenotypic evidence of leukemia after induction therapy predicts relapse: results from a prospective Children's Cancer Group study of 252 patients with acute myeloid leukemia.
Sievers EL; Lange BJ; Alonzo TA; Gerbing RB; Bernstein ID; Smith FO; Arceci RJ; Woods WG; Loken MR
Blood; 2003 May; 101(9):3398-406. PubMed ID: 12506020
[TBL] [Abstract][Full Text] [Related]
45. Secondary acute myelogenous leukemia and myelodysplasia without abnormalities of chromosome 11q23 following treatment of acute leukemia with topoisomerase II-based chemotherapy.
Seiter K; Feldman EJ; Sreekantaiah C; Pozzuoli M; Weisberger J; Liu D; Papageorgio C; Weiss M; Kancherla R; Ahmed T
Leukemia; 2001 Jun; 15(6):963-70. PubMed ID: 11417484
[TBL] [Abstract][Full Text] [Related]
46. Remission induction therapy: the more intensive the better?
Büchner T; Hiddemann W; Berdel W; Wörmann B; Löffler H; Schoch C; Haferlach T; Ludwig WD; Maschmeyer G; Staib P; Andreesen R; Balleisen L; Haase D; Eimermacher H; Aul C; Rasche H; Uhlig J; Grüneisen A; Reis HE; Hartlapp J; Hirschmann WD; Weh HJ; Pielken HJ; Gassmann W; Sauerland MC; Heinecke A
Cancer Chemother Pharmacol; 2001 Aug; 48 Suppl 1():S41-4. PubMed ID: 11587366
[TBL] [Abstract][Full Text] [Related]
47. High dose cytarabine and mitoxantrone: an effective induction regimen for high-risk acute myeloid leukemia (AML).
Larson SM; Campbell NP; Huo D; Artz A; Zhang Y; Gajria D; Green M; Weiner H; Daugherty C; Odenike O; Godley LA; Hyjek E; Gurbuxani S; Thirman M; Sipkins D; Van Besien K; Larson RA; Stock W
Leuk Lymphoma; 2012 Mar; 53(3):445-50. PubMed ID: 21913806
[TBL] [Abstract][Full Text] [Related]
48. Prognostic impact of karyotype and immunologic phenotype in 125 adult patients with de novo AML.
Marosi C; Köller U; Koller-Weber E; Schwarzinger I; Schneider B; Jäger U; Vahls P; Nowotny H; Pirc-Danoewinata H; Steger G
Cancer Genet Cytogenet; 1992 Jul; 61(1):14-25. PubMed ID: 1638477
[TBL] [Abstract][Full Text] [Related]
49. Flow cytometry-based assessment of mitoxantrone efflux from leukemic blasts varies with response to induction chemotherapy in acute myeloid leukemia.
Kim HP; Bernard L; Berkowitz J; Nitta J; Hogge DE
Cytometry B Clin Cytom; 2012 Sep; 82(5):283-94. PubMed ID: 22508650
[TBL] [Abstract][Full Text] [Related]
50. Autologous bone marrow transplantation versus intensive consolidation chemotherapy for acute myeloid leukemia in childhood. Pediatric Oncology Group.
Ravindranath Y; Yeager AM; Chang MN; Steuber CP; Krischer J; Graham-Pole J; Carroll A; Inoue S; Camitta B; Weinstein HJ
N Engl J Med; 1996 May; 334(22):1428-34. PubMed ID: 8618581
[TBL] [Abstract][Full Text] [Related]
51. Deficient expression of NCR in NK cells from acute myeloid leukemia: Evolution during leukemia treatment and impact of leukemia cells in NCRdull phenotype induction.
Fauriat C; Just-Landi S; Mallet F; Arnoulet C; Sainty D; Olive D; Costello RT
Blood; 2007 Jan; 109(1):323-30. PubMed ID: 16940427
[TBL] [Abstract][Full Text] [Related]
52. Acute myeloid leukemia (AML) in Down's syndrome is highly responsive to chemotherapy: experience on Pediatric Oncology Group AML Study 8498.
Ravindranath Y; Abella E; Krischer JP; Wiley J; Inoue S; Harris M; Chauvenet A; Alvarado CS; Dubowy R; Ritchey AK
Blood; 1992 Nov; 80(9):2210-4. PubMed ID: 1384797
[TBL] [Abstract][Full Text] [Related]
53. Gene rearrangements in bone marrow cells of patients with acute myelogenous leukemia.
Schmetzer HM; Braun S; Wiesner D; Duell T; Gerhartz HH; Mittermueller J
Acta Haematol; 2000; 103(3):125-34. PubMed ID: 10940650
[TBL] [Abstract][Full Text] [Related]
54. Autologous transplantation of chemotherapy-purged PBSC collections from high-risk leukemia patients: a pilot study.
Lemoli RM; Visani G; Leopardi G; Motta MR; Rizzi S; Testoni N; Curti A; Tura S
Bone Marrow Transplant; 1999 Feb; 23(3):235-41. PubMed ID: 10084254
[TBL] [Abstract][Full Text] [Related]
55. Diagnostic criteria for hypocellular acute leukemia: a clinical entity distinct from overt acute leukemia and myelodysplastic syndrome.
Nagai K; Kohno T; Chen YX; Tsushima H; Mori H; Nakamura H; Jinnai I; Matsuo T; Kuriyama K; Tomonaga M; Bennett JM
Leuk Res; 1996 Jul; 20(7):563-74. PubMed ID: 8795690
[TBL] [Abstract][Full Text] [Related]
56. Recombinant human granulocyte-macrophage colony-stimulating factor after chemotherapy in patients with acute myeloid leukemia at higher age or after relapse.
Büchner T; Hiddemann W; Koenigsmann M; Zühlsdorf M; Wörmann B; Boeckmann A; Freire EA; Innig G; Maschmeyer G; Ludwig WD
Blood; 1991 Sep; 78(5):1190-7. PubMed ID: 1878586
[TBL] [Abstract][Full Text] [Related]
57. In vitro and in vivo effects of rh GM-CSF in acute myeloid leukemia (AML).
Wörmann B; Hiddemann W; Frisch J; Zühlsdorf M; Rottmann R; Boeckmann A; Reuter C; Freire EA; Innig G; Schulz G
Behring Inst Mitt; 1991 Dec; (90):28-38. PubMed ID: 1801688
[TBL] [Abstract][Full Text] [Related]
58. Outcome of induction and postremission therapy in younger adults with acute myeloid leukemia with normal karyotype: a cancer and leukemia group B study.
Farag SS; Ruppert AS; Mrózek K; Mayer RJ; Stone RM; Carroll AJ; Powell BL; Moore JO; Pettenati MJ; Koduru PR; Stamberg J; Baer MR; Block AW; Vardiman JW; Kolitz JE; Schiffer CA; Larson RA; Bloomfield CD
J Clin Oncol; 2005 Jan; 23(3):482-93. PubMed ID: 15534356
[TBL] [Abstract][Full Text] [Related]
59. [Current and new therapeutic strategies in acute myeloid leukemia].
Naito K; Ohnishi K
Gan To Kagaku Ryoho; 2005 Mar; 32(3):292-6. PubMed ID: 15791811
[TBL] [Abstract][Full Text] [Related]
60. Maintenance therapy in childhood acute myeloid leukemia.
Perel Y; Auvrignon A; Leblanc T; Michel G; Vannier JP; Dalle JH; Gandemer V; Schmitt C; Mèchinaud F; Lamagnere JP; Piguet Ch; Couillaud G; Pautard B; Baruchel A; Leverger G; ;
Ann Hematol; 2004; 83 Suppl 1():S116-9. PubMed ID: 15124700
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
